Compare XBIT & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | LNZA |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 61.2M |
| IPO Year | 2015 | 2021 |
| Metric | XBIT | LNZA |
|---|---|---|
| Price | $2.20 | $6.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 45.0K | ★ 53.1K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.00 |
| Revenue | N/A | ★ $55,845,000.00 |
| Revenue This Year | N/A | $55.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.36 |
| Revenue Growth | N/A | ★ 12.61 |
| 52 Week Low | $2.09 | $5.02 |
| 52 Week High | $3.44 | $44.00 |
| Indicator | XBIT | LNZA |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 52.25 |
| Support Level | $2.21 | $5.32 |
| Resistance Level | $2.46 | $6.63 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 11.76 | 55.11 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.